GLP-1 Evidence

Trygd

GLP-1 bívøttir, raðfest eftir tíðni

Gastrointestinal bíðingarevnir eru næstan universell og vanliga stýrandi. Tær sjaldnu hendingarnar, sum dominera umfjørðina, eru veruliga sjaldnar.

Uppdatert 3 min lesing 27 tilvísingar Dokumentasjonsstyrkur 4/5

Ytursýni av einum sjúkrahúsarbeddi og skáp í einum felagsdeildarherbergi
玄史生 · CC0 · Wikimedia Commons

Tær vanligu

Næstan alt, sum er vanligt, er gastrointestinalt, og næstan alt fylgir beinleiðis av seinkaðari gastrisk tøming. Ígjøgnum royndarprogramini er mynstrið samanhangandi [5][6][8]:

Typisk tíðarskeið frá teimum randomiserðu royndunum
ÁvirkanUmleið hvussu vanligMynstur
KvalmiVøttulig vanlig (ein triðingur til ein hálvpartur)Hækka eftir hvørja doyping hækking, so javnar tað seg
DiarreaVanligOftast tíðliga, vanliga tímabundin
ForstoppelseVanligKann halda fram; oftast tann meira irriteraðandi langtíðarklaga
BrekVanligSterkt doyping-bundin
Miðvøttur, reflux, belgingVanligVanliga mild
Reaksjónir á doypistøðunumÓvanligMild
Støttan vegna bíðingarevnirNokkur prosentHækkar við hægri doypingum

Gapið millum "ein triðingur av fólki følir seg sjúkt" og "nokkra prosent stopp" er tað mest gagnliga tal her. Flestu fólk, sum fáa kvalma, halda fram, vanliga tí tað batnar.

Tær sjaldnu, sum fólk eru bekymrað um

Pankreatitis, gallbløðrasjúka, skjaldkirtil C-frumtumør og gastroparesis dominera online umrøðu langt út av proporción til teirra tíðni í dátuni.

  • Gallbløðrasjúka. Veruliga økt, men hetta er í stóran mun ein fylgja av skjótt vættat tapi heldur enn beinleiðis medisinar toksisitet — skjótt vættat tapi við hvørjum móti hækkar gallsteinsrisika.
  • Pankreatitis. Vakt intensivt yvir øll flokk. Stórar meta-analyser av hjarta- og nýru úrslitroyndum hava ikki framleitt signal, sum fyrstu tilfellini vístu [1].
  • Skjaldkirtil C-frumtumør. Varningin kemur frá rottustudium. Tað hevur ikki broytt seg í eina demonstreraða menneskiliga signal, men tað er tí, at medisinar eru kontraindiceret við persónligum ella familjuni søgu um medullary skjaldkirtil carcinoma ella MEN2.
  • Gastroparesis. Seinkað gastrisk tøming er ætlaði mekanismin, sum er umrøtt á mekanismu síðuni. Alvarlig viðvarandi gastroparesis er ein aðrasta og nógv sjaldnari ting.

Fráver av stórum trygdarsignalum í samansetta royndardatuni

Hvat nýggju munnligu evnini líta út

Munnligu smá-molekular agonistarnir hava nú verið ígjøgnum stórar randomiserðar royndir í bæði feitt og tíðligum týpu 2 diabetes [2][3][4]. Deras toleransprofil sær út sum tær injektiblu — dominerað av somu gastrointestinalum ávirkanum, við somu doyping hækkingsstrategi. At vera ein pilla broytir ikki mekanismin, og tí broytir tað ikki bíðingarevnir. Meira um tey munnligu valini.

Hvar royndardata og veruleikin divergera

Royndarfólk eru skannað, yvirvøtt og hækkað á protokoll. Ein 2025 ummæli av veruleikabrúki og effektivitet fann, at breiða trygdabildið heldur seg uttan royndir, men við meira variabilitet — drívið av skjótari hækking, doyping avbjóðingar, tilfeingisgap og samansetta produkt av óvissum innihaldi [9]. Flestu av teimum versta úrslitunum, sum eru umtalað uttan royndir, viðvíkja ikki-tilskilað sourcing heldur enn medisinar sjálvar.

Hvít filmhúðaðar tabletur í einum blisterstripi
Cindy Shebley · CC BY 2.0 · Wikimedia Commons

Vanlig spurningar

Følger kvalman nakrantíð burtur heilt?
Fyrst og fremst javnar tað seg innan vikur av eini givnu doyping, og kemur aftur stutt við hvørja hækking. Forstoppelse er ávirkanin, sum er mest lík til at halda fram.
Er hártap ein bíðingarevni?
Hárfelling er ein væl kend fylgja av skjótt vættat tapi í almenna — telogen effluvium — heldur enn ein serligur medisinar toksisitet. Tað er vanliga tímabundið.
Skal eg stoppa áðrenn kirurgi?
Spyrja tína anestesist. Tað er serlig perioperativ leiðbeining, tí magesekkurin kann ikki vera tøttur eftir standard fasta.
Betyr bíðingarevnir, at tað virkar?
Nei. Kvalmi og vættat tapi eru bæði doyping-bundin, men einstaklingar variere vítt í báðum. Mikið fólk missa nógv av vættat tapi uttan nógv kvalma.
Evidensin fyri hesa síðu Ein stakkur bar, sum vísir samansetingina av 12 útgávunum, sum eru nevndar á hesi síðu eftir rannsóknartypum. 1911meta-analysis (1)randomised trial (9)review (1)other (1)
9 útgávur, 2018–2025. Her eru royndir, men lítið samansjóðing, so einstakar úrslit hava framvegis nógv at siga og kunnu broytast. Kelda: egnu tilvísingalistin á hesi síðu, niðanfyri.

Viðmerkingar

Hver einasta tilvísing niðanfyri bendir til upprunaliga peer-reviewed skjalið á PubMed ella gjøgnum DOI. Einki her er ein staðfesting fyri læknaligt ráð.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  3. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  4. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text
  5. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  6. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  7. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  8. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Cummings JL, Atri A, Sano M, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41865758
  9. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, et al. · The lancet. Diabetes & endocrinology · 2026 · Randomised controlled trial DOIPubMed 42251859
  10. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025 · Randomised controlled trial DOIPubMed 40975112
  11. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544435
  12. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  13. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Blüher M, Rosenstock J, Hoefler J, et al. · Diabetologia · 2024 · Randomised controlled trial DOIPubMed 38095657Full text
  14. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  15. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  16. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Wharton S, Blevins T, Connery L, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37351564
  17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  18. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Inagaki N, Takeuchi M, Oura T, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35914543
  19. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34170647
  21. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Thomas MK, Nikooienejad A, Bray R, et al. · The Journal of clinical endocrinology and metabolism · 2021 · Randomised controlled trial DOIPubMed 33236115Full text
  22. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Yamada Y, Katagiri H, Hamamoto Y, et al. · The lancet. Diabetes & endocrinology · 2020 · Randomised controlled trial DOIPubMed 32333875
  23. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  24. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  25. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes, obesity & metabolism · 2025 · Review DOIPubMed 40196933Full text
  26. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083
  27. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Aroda VR, Rosenstock J, Terauchi Y, et al. · Diabetes care · 2019 · Journal article DOIPubMed 31186300

Henda síða varð sjálvvirkandi týdd úr enskt. Tilvísingarnar og tølini eru óbroytt. Les upprunaliga enska útgávuna um nakað lesist undarliga. Les upprunaliga enska útgávuna